Literature DB >> 25501566

APOBEC3 enzymes restrict marginal zone B cells.

Gabriele B Beck-Engeser1, Rebecca Winkelmann, Matthew L Wheeler, Maryam Shansab, Philipp Yu, Sarah Wünsche, Anja Walchhütter, Mirjam Metzner, Christian Vettermann, Dan Eilat, Anthony DeFranco, Hans-Martin Jäck, Matthias Wabl.   

Abstract

In general, a long-lasting immune response to viruses is achieved when they are infectious and replication competent. In the mouse, the neutralizing antibody response to Friend murine leukemia virus is contributed by an allelic form of the enzyme Apobec3 (abbreviated A3). This is counterintuitive because A3 directly controls viremia before the onset of adaptive antiviral immune responses. It suggests that A3 also affects the antibody response directly. Here, we studied the relative size of cell populations of the adaptive immune system as a function of A3 activity. We created a transgenic mouse that expresses all seven human A3 enzymes and compared it to WT and mouse A3-deficient mice. A3 enzymes decreased the number of marginal zone B cells, but not the number of follicular B or T cells. When mouse A3 was knocked out, the retroelement hitchhiker-1 and sialyl transferases encoded by genes close to it were overexpressed three and two orders of magnitude, respectively. We suggest that A3 shifts the balance, from the fast antibody response mediated by marginal zone B cells with little affinity maturation, to a more sustained germinal center B-cell response, which drives affinity maturation and, thereby, a better neutralizing response.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Apobec3; B cell; Hitchhiker-1; Recovery from Friend virus 3 (Rfv3); Sialyl transferases

Mesh:

Substances:

Year:  2015        PMID: 25501566      PMCID: PMC4972502          DOI: 10.1002/eji.201445218

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  31 in total

Review 1.  Marginal zone B cells.

Authors:  Shiv Pillai; Annaiah Cariappa; Stewart T Moran
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

2.  APOBEC3 proteins inhibit human LINE-1 retrotransposition.

Authors:  Heide Muckenfuss; Matthias Hamdorf; Ulrike Held; Mario Perkovic; Johannes Löwer; Klaus Cichutek; Egbert Flory; Gerald G Schumann; Carsten Münk
Journal:  J Biol Chem       Date:  2006-05-30       Impact factor: 5.157

3.  Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses.

Authors:  A M Oliver; F Martin; G L Gartland; R H Carter; J F Kearney
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

4.  Incorporation of mouse APOBEC3 into murine leukemia virus virions decreases the activity and fidelity of reverse transcriptase.

Authors:  Stefano Boi; Angelo Kolokithas; Joyce Shepard; Rebecca Linwood; Kyle Rosenke; Erik Van Dis; Frank Malik; Leonard H Evans
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

5.  Transcription originating in the long terminal repeats of the endogenous mouse mammary tumor virus MTV-3 is activated in Stat5a-null mice and picks Up hitchhiking exons.

Authors:  S S Stegalkina; A Guerrero; K D Walton; X Liu; G W Robinson; L Hennighausen
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 6.  Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.

Authors:  Andrea Cerutti; Montserrat Cols; Irene Puga
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

7.  Expansion of marginal zone B cells is not sufficient for the development of renal disease in NZBxNZW F1 mice.

Authors:  H Schuster; T Martin; L Marcellin; J C Garaud; J L Pasquali; A S Korganow
Journal:  Lupus       Date:  2002       Impact factor: 2.911

8.  Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response.

Authors:  Diana S Smith; Kejun Guo; Bradley S Barrett; Karl J Heilman; Leonard H Evans; Kim J Hasenkrug; Warner C Greene; Mario L Santiago
Journal:  PLoS Pathog       Date:  2011-10-06       Impact factor: 6.823

9.  B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase.

Authors:  Annaiah Cariappa; Hiromu Takematsu; Haoyuan Liu; Sandra Diaz; Khaleda Haider; Cristian Boboila; Geetika Kalloo; Michelle Connole; Hai Ning Shi; Nissi Varki; Ajit Varki; Shiv Pillai
Journal:  J Exp Med       Date:  2008-12-22       Impact factor: 14.307

10.  LINE-1 retroelements complexed and inhibited by activation induced cytidine deaminase.

Authors:  Mirjam Metzner; Hans-Martin Jäck; Matthias Wabl
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

View more
  6 in total

1.  Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Authors:  Jan Budczies; Anja Seidel; Petros Christopoulos; Volker Endris; Matthias Kloor; Balázs Győrffy; Barbara Seliger; Peter Schirmacher; Albrecht Stenzinger; Carsten Denkert
Journal:  Oncoimmunology       Date:  2018-10-19       Impact factor: 8.110

2.  Type I interferon signaling is required for the APOBEC3/Rfv3-dependent neutralizing antibody response but not innate retrovirus restriction.

Authors:  Bradley S Barrett; Michael S Harper; Sean T Jones; Kejun Guo; Karl J Heilman; Ross M Kedl; Kim J Hasenkrug; Mario L Santiago
Journal:  Retrovirology       Date:  2017-04-17       Impact factor: 4.602

Review 3.  APOBEC3B, a molecular driver of mutagenesis in human cancers.

Authors:  Jun Zou; Chen Wang; Xiangyi Ma; Edward Wang; Guang Peng
Journal:  Cell Biosci       Date:  2017-05-30       Impact factor: 7.133

4.  Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.

Authors:  Alba Mota; Sara S Oltra; Pier Selenica; Cristian P Moiola; Carlos Casas-Arozamena; Carlos López-Gil; Eva Diaz; Sonia Gatius; María Ruiz-Miro; Ana Calvo; Alejandro Rojo-Sebastián; Pablo Hurtado; Roberto Piñeiro; Eva Colas; Antonio Gil-Moreno; Jorge S Reis-Filho; Laura Muinelo-Romay; Miguel Abal; Xavier Matias-Guiu; Britta Weigelt; Gema Moreno-Bueno
Journal:  Oncogene       Date:  2022-02-10       Impact factor: 9.867

Review 5.  APOBEC3B: Future direction of liver cancer research.

Authors:  Xingyue Yang; Jing Dai; Shun Yao; Jiaxing An; Guorong Wen; Hai Jin; Li Zhang; Liming Zheng; Xingyue Chen; Zhiqiang Yi; Biguang Tuo
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

6.  Systemic ST6Gal-1 Is a Pro-survival Factor for Murine Transitional B Cells.

Authors:  Eric E Irons; Joseph T Y Lau
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.